Vaccines and Catch-Up in 2026: Schedule Navigation, Documentation, and Vaccine Confidence for Clinicians
Abstract
Purpose: This review provides a comprehensive overview of contemporary vaccine practice in 2026, with emphasis on immunization schedule navigation, catch up vaccination, documentation standards, vaccine safety, product specific recommendations, and evidence based communication strategies for addressing vaccine confidence. As immunization guidelines continue to evolve in response to emerging pathogens, new vaccine technologies, and expanding indications for existing products, clinicians must move beyond memorizing fixed schedules toward applying dynamic, patient centered decision making. The review aims to equip healthcare professionals with practical guidance for interpreting current recommendations across diverse patient populations, including infants, children, adolescents, adults, pregnant individuals, older adults, and immunocompromised patients. Particular attention is given to integrating age based, risk based, and condition specific recommendations into routine clinical practice while maintaining patient safety, regulatory compliance, and high quality preventive care.
Methodology: This narrative review synthesizes evidence from authoritative national guidelines, regulatory documents, and contemporary scientific literature relevant to vaccine practice in 2026. Primary sources include the current Centers for Disease Control and Prevention immunization schedules and General Best Practice Guidelines for Immunization, the 2026 American Academy of Pediatrics Childhood and Adolescent Immunization Schedule, the 2026 American College of Obstetricians and Gynecologists Maternal Immunization Schedule, United States Food and Drug Administration vaccine labeling and safety communications, and recommendations published in the Morbidity and Mortality Weekly Report. Additional evidence was obtained from pivotal randomized controlled trials evaluating respiratory syncytial virus vaccines, systematic reviews, meta analyses, and clinical trials examining vaccine safety, effectiveness, immunogenicity, and communication interventions designed to improve vaccine acceptance. The review also incorporates evidence regarding documentation standards, catch up immunization protocols, contraindications, precautions, and shared decision making to provide a comprehensive framework for contemporary vaccine delivery.
Main Findings: Vaccine administration in 2026 requires clinicians to navigate increasingly complex and frequently updated immunization schedules rather than relying on memorized recommendations. Appropriate vaccine selection now depends on the integration of multiple clinical variables, including patient age, underlying medical conditions, pregnancy status, occupational exposure, travel history, immunocompromising conditions, previous vaccination history, and product specific indications. Accurate implementation requires continuous reference to current recommendations as schedules are regularly revised in response to emerging evidence and public health priorities.
Catch up immunization remains a fundamental component of clinical practice, particularly for patients with delayed or incomplete vaccination histories. Current evidence consistently supports continuing interrupted vaccine series without restarting them, regardless of the time elapsed since the previous dose. However, clinicians must carefully verify the validity of all previously administered doses by confirming the patient’s age at vaccination, minimum intervals between doses, appropriate vaccine formulation, route of administration, and reliable documentation. Careful assessment prevents unnecessary repeat vaccination while ensuring that incomplete or invalid doses are appropriately addressed according to current guidelines.
Comprehensive documentation continues to play a critical role in vaccine safety, continuity of care, and public health surveillance. Accurate records should include vaccine product name, manufacturer, lot number, expiration date, dose, route, anatomical site of administration, date of administration, Vaccine Information Statement or equivalent educational material provided, and documentation of informed consent or patient refusal when applicable. Robust documentation practices facilitate future clinical decision making, improve interoperability between healthcare systems, and strengthen vaccine safety monitoring programs.
Safety assessment remains central to every vaccination encounter. Clinicians must distinguish true contraindications from temporary precautions and common misconceptions that unnecessarily delay immunization. Current recommendations continue to emphasize individualized risk benefit assessment, particularly for pregnant patients, immunocompromised individuals, older adults, and patients with previous adverse reactions. Ongoing pharmacovigilance systems and post marketing surveillance continue to demonstrate that licensed vaccines maintain favorable safety profiles, while prompt recognition and reporting of adverse events contribute to continual refinement of vaccine recommendations and public confidence.
The rapid expansion of vaccine products has increased the importance of product specific recommendations. Differences in age indications, dosing schedules, interchangeability, storage requirements, and clinical indications require careful product selection to ensure optimal immunogenicity and regulatory compliance. The introduction of new respiratory syncytial virus vaccines, updated coronavirus vaccines, and evolving pneumococcal and influenza recommendations further underscores the need for clinicians to remain current with changing guidance rather than relying on historical practice patterns.
Effective communication regarding vaccination has become an increasingly important clinical competency as vaccine hesitancy continues to influence preventive healthcare. Current evidence supports a practical, patient centered approach that begins with a confident and unequivocal clinician recommendation, followed by exploration of the patient’s specific questions or concerns. Successful counseling involves acknowledging uncertainty where it exists, distinguishing established scientific evidence from evolving knowledge, correcting misinformation respectfully, and engaging patients in shared decision making without judgment or coercion. Documentation of vaccine discussions should accurately reflect the information provided, patient preferences, and the final clinical decision while avoiding stigmatizing or adversarial language.
Although numerous communication strategies have been evaluated, the available evidence remains heterogeneous. No single intervention has consistently demonstrated superiority across all populations, healthcare settings, or cultural contexts. Vaccine confidence is influenced by complex interactions among individual beliefs, healthcare experiences, community trust, cultural values, misinformation, and health literacy. Consequently, effective communication requires flexibility, empathy, and adaptation to each patient’s informational needs rather than reliance on standardized messaging alone.
In summary, vaccine practice in 2026 has evolved into a dynamic, evidence driven discipline requiring clinicians to integrate continuously updated recommendations with individualized patient assessment and effective communication. Success depends on accurate schedule navigation, meticulous documentation, adherence to product specific guidance, evidence based safety assessment, and patient centered counseling that promotes informed decision making. As immunization science continues to advance and vaccine recommendations become increasingly sophisticated, clinicians must remain committed to lifelong learning and the consistent application of current evidence to optimize individual patient outcomes and strengthen public health.
Keywords: immunization schedule, catch-up vaccination, vaccine documentation, vaccine hesitancy, adult immunization, RSV vaccine, COVID-19 vaccine, shared clinical decision-making
Introduction
Vaccination has evolved from a straightforward preventive intervention into a complex clinical quality and reliability challenge. In contemporary healthcare practice, the critical question is no longer whether clinicians recognize the importance of immunization. Instead, the challenge lies in ensuring that every patient encounter consistently results in an accurate assessment of vaccination status, timely identification of recommended vaccines, appropriate product selection, recognition of contraindications and precautions, and effective patient counseling. Achieving this level of consistency requires well designed clinical systems that support evidence based decision making across diverse healthcare settings.
The complexity of adult immunization has increased considerably over the past decade. Expanding vaccine recommendations, evolving epidemiology, the introduction of new vaccine platforms, changing age and risk based indications, and frequent updates to national immunization schedules have created a dynamic landscape that demands continual clinical vigilance. Healthcare professionals practicing in busy outpatient clinics, inpatient services, emergency departments, pharmacies, specialty practices, and transitional care settings must rapidly determine whether patients are due for routine immunizations, require catch up vaccination, or qualify for additional vaccines based on medical conditions, immunocompromising therapies, occupational exposure, travel, or lifestyle factors. They must also verify the validity of previous doses, identify appropriate dosing intervals, avoid unnecessary revaccination, and ensure accurate documentation within increasingly interconnected electronic health record systems.
These challenges are particularly relevant for physicians and advanced practitioners caring for adults with chronic medical conditions. Internal medicine subspecialists frequently manage patients whose underlying diseases or therapeutic regimens substantially increase susceptibility to vaccine preventable infections and their complications. Cardiologists care for patients with heart failure, ischemic heart disease, and arrhythmias in whom respiratory viral infections may precipitate acute cardiovascular events. Pulmonologists manage individuals with chronic obstructive pulmonary disease, asthma, interstitial lung disease, and other respiratory disorders that are highly vulnerable to influenza, respiratory syncytial virus, coronavirus disease 2019, and pneumococcal infection. Nephrologists treat patients with chronic kidney disease and those receiving dialysis who often exhibit impaired immune responses and elevated infection related mortality.
Similarly, endocrinologists care for individuals with diabetes mellitus, a population known to experience increased morbidity from influenza, pneumococcal disease, and hepatitis B infection. Gastroenterologists and hepatologists frequently manage patients with chronic liver disease or inflammatory bowel disease receiving immunosuppressive therapy, both of which influence vaccine selection and timing. Rheumatologists, oncologists, transplant physicians, and hematologists routinely prescribe immunomodulatory agents that increase vulnerability to opportunistic and vaccine preventable infections while simultaneously altering vaccine effectiveness and safety considerations. Infectious diseases specialists, pharmacists, nurse practitioners, physician associates, and other advanced practice clinicians also play indispensable roles in identifying immunization gaps, coordinating vaccine delivery, and reinforcing preventive care throughout the healthcare continuum.
The consequences of missed vaccination opportunities in these high risk populations can be profound. Vaccine preventable infections such as influenza, coronavirus disease 2019, pneumococcal disease, respiratory syncytial virus infection, hepatitis B, varicella, herpes zoster, meningococcal disease, and other preventable illnesses may trigger severe complications including cardiopulmonary decompensation, acute exacerbations of chronic disease, secondary bacterial infections, prolonged hospitalization, interruption of chemotherapy or immunosuppressive treatment, graft dysfunction, intensive care admission, and death. Beyond individual patient outcomes, inadequate vaccine coverage contributes to increased healthcare expenditures, greater healthcare system strain, and preventable disease transmission within vulnerable populations.
An additional challenge arises from the increasing complexity of vaccine recommendations themselves. Adult immunization schedules now incorporate age based, condition specific, shared clinical decision making, and risk based recommendations that differ according to underlying medical conditions, pregnancy status, immune function, previous vaccination history, and evolving public health guidance. Clinicians must distinguish between live attenuated and non live vaccines, determine appropriate timing relative to immunosuppressive therapy or transplantation, recognize temporary versus permanent contraindications, and understand precautions that may require delaying rather than withholding vaccination. Accurate assessment of prior immunization records, vaccine intervals, minimum ages, and product interchangeability has become essential for ensuring both effectiveness and patient safety.
Equally important is the need to address vaccine confidence through effective communication. Vaccine hesitancy remains a significant barrier to adult immunization despite overwhelming evidence supporting vaccine safety and effectiveness. Patients frequently express concerns regarding adverse effects, vaccine necessity, misinformation encountered through digital media, or uncertainty about changing recommendations. Clinicians therefore require strong communication skills that combine scientific accuracy with empathy, active listening, and shared decision making. Clear explanations of individual disease risk, expected benefits, potential adverse events, and the rationale for specific recommendations can improve vaccine acceptance and strengthen therapeutic relationships.
Given these challenges, the central objective of immunization practice in 2026 is not the memorization of increasingly detailed vaccine schedules. Rather, it is the development of reliable, standardized clinical processes that consistently support evidence based vaccination at every point of care. Effective systems incorporate routine vaccine status review during patient encounters, structured catch up protocols, integration of electronic clinical decision support tools, accurate documentation within immunization registries, verification of previous doses, careful assessment of contraindications and precautions, and timely administration of recommended vaccines. These processes should be embedded into routine clinical workflows rather than relying solely on individual clinician memory.
Multidisciplinary collaboration further strengthens vaccine delivery. Physicians, pharmacists, nurses, advanced practice clinicians, medical assistants, and public health professionals each contribute to identifying vaccination opportunities, educating patients, maintaining accurate records, and ensuring completion of multidose vaccine series. Electronic health records, clinical reminders, standing orders, and immunization information systems have become valuable tools for reducing missed opportunities and improving adherence to current recommendations.
Ultimately, successful adult immunization programs depend on creating dependable systems that integrate accurate clinical assessment, evidence based recommendations, patient centered communication, and coordinated team based care. As vaccine recommendations continue to evolve alongside changing epidemiology and emerging infectious threats, healthcare professionals must shift their focus from memorizing schedules to implementing reproducible processes that ensure every eligible patient receives appropriate, timely, and safe vaccination. This systems based approach represents the foundation of high quality preventive care and is essential for reducing the burden of vaccine preventable disease across all areas of adult medicine.
Why Vaccine Practice Is More Complex in 2026
Vaccine schedules have become increasingly product-specific and risk-stratified. Pneumococcal recommendations depend on age, medical risk, and the patient’s history of conjugate and polysaccharide vaccines. RSV vaccination requires attention to age, risk factors, pregnancy, prior RSV vaccination, product labeling, and evolving safety information. COVID-19 schedules vary by age, vaccination history, immune status, and product. Pentavalent MenABCWY products can simplify selected visits when both MenACWY and MenB vaccination are indicated, but they do not eliminate product- and series-specific requirements.
National guidance also does not currently appear in one fully harmonized document. As of July 27, 2026, CDC identifies its July 2, 2025 childhood and adult schedules, with a subsequent adult RSV amendment, as the current CDC schedules following a preliminary federal court order. AAP has published a separate 2026 childhood and adolescent schedule, and ACOG has published a separate 2026 maternal immunization schedule that differs from current federal recommendations in several areas.
Clinicians caring for children, adolescents, pregnant or postpartum patients, immunocompromised hosts, or other special populations should therefore verify the current CDC schedule, relevant specialty-society guidance, FDA labeling, institutional policy, state requirements, and local public health recommendations at the time of care.
This article emphasizes schedule navigation rather than reproducing every dose or interval. The controlling sources for an individual patient remain the current applicable schedule, product labeling, contraindication and precaution guidance, and relevant state or institutional policy.
A Functional Framework for Vaccine Review
A vaccine review should answer four questions.
First, what has the patient already received, and how reliable is the record? Second, which vaccines are routinely indicated by age? Third, which additional vaccines are indicated by medical condition, medication exposure, pregnancy, occupation, travel, sexual exposure, asplenia, immunocompromised status, outbreak status, or residence in a congregate setting? Fourth, are there contraindications, precautions, product restrictions, timing issues, or documentation gaps?
A reliable review begins with records. The electronic health record alone is often incomplete because vaccines may be administered in pharmacies, health departments, employer clinics, travel clinics, dialysis units, obstetric practices, retail settings, or other health systems. State immunization information systems, pharmacy records, prior medical records, patient-held cards, military records, occupational records, and selected serologic testing may all be useful.
Patient report can provide useful context but should not automatically be treated as equivalent to documented vaccination. A report of a recent influenza vaccine may help guide the immediate discussion, but verbal recall is less reliable when reconstructing multidose series, establishing immunity to measles or varicella, confirming hepatitis B vaccination, or determining which pneumococcal vaccine products and doses were previously administered.
Table 1. High-Yield Vaccine Review in Adult and Subspecialty Practice
| Clinical setting | Vaccines to actively review | Key qualifier |
| Cardiology and pulmonary care | Influenza, COVID-19, pneumococcal, RSV | Review by age, cardiopulmonary risk, prior products, and current respiratory-virus guidance |
| Nephrology and dialysis | Hepatitis B, influenza, COVID-19, pneumococcal | Vaccine response may be reduced in advanced kidney disease; coordinate with dialysis and transplant planning |
| Rheumatology, IBD, oncology, and transplant | Inactivated vaccines, recombinant zoster, pneumococcal, hepatitis B, influenza, COVID-19 | Review before immunosuppression when feasible; live-vaccine eligibility depends on immune status and therapy |
| Pregnancy and postpartum care | Influenza, COVID-19, Tdap, maternal RSV when indicated | Verify the applicable maternal schedule, gestational timing, product, season, and prior maternal RSV vaccination |
| Unknown or fragmented records | Age-based and risk-based vaccines | Query registries and outside records; do not infer a complete series from vague recall |
Catch-Up Immunization: Continue the Series Unless Guidance Says Otherwise
A common catch-up error is restarting a vaccine series because too much time has elapsed. For routinely administered vaccines, an extended interval generally does not invalidate otherwise valid prior doses. The appropriate approach is to identify valid prior doses and continue from the last valid dose unless current vaccine-specific guidance states otherwise.
The difficult question is often not immunologic. It is whether the earlier dose counts. Dose validity may depend on the patient’s age at administration, minimum age, minimum interval from a prior dose, grace-period rules, product, route, and vaccine-specific schedule. A dose administered too early may need to be repeated. A dose administered after a prolonged gap usually does not.
Catch-up decisions should distinguish three concepts:
Documented dose: A dose supported by a reliable vaccination record.
Valid dose: A documented dose administered at an acceptable age and interval, using the correct product and route when vaccine-specific requirements apply.
Complete series: A sequence of valid doses satisfying the current age-based, risk-based, or catch-up schedule.
Partial histories require caution. “Three tetanus shots” does not establish whether the patient completed an appropriate primary series, received Tdap, or received boosters only. “Pneumonia shot” could refer to PCV13, PCV15, PCV20, PCV21, PPSV23, or an uncertain product. “Meningitis vaccine” could mean MenACWY, MenB, or a pentavalent MenABCWY vaccine. The source, date, product, and certainty of the information should be documented.
Table 2. Catch-Up Workflow for Clinicians
| Step | Action | Common error to avoid |
| Reconstruct history | Query the EHR, immunization registry, pharmacies, prior clinicians, and patient-held records | Accepting vague recall as proof of a complete series |
| Validate doses | Check minimum age, interval, product, route, and applicable grace-period rules | Counting an early or otherwise invalid dose |
| Identify modifiers | Review pregnancy, immunosuppression, asplenia, kidney disease, travel, occupation, and exposure risk | Applying only the routine age-based schedule |
| Continue the series | Administer the next indicated dose when appropriate | Restarting a valid series unnecessarily |
| Close the loop | Schedule the next dose and document the plan | Leaving multidose follow-up to patient or clinician memory |
Documentation Is a Safety Intervention
Vaccination documentation is not clerical housekeeping. Accurate documentation helps prevent unnecessary repeat vaccination, missed catch-up doses, invalid school or occupational records, and uncertainty during adverse-event review. It also improves continuity when patients receive vaccines across multiple settings.
For vaccines covered by federal documentation requirements, the permanent record must include the administration date, manufacturer, lot number, and the name, address, and title of the person administering the vaccine. The edition date of the Vaccine Information Statement and the date it was provided must also be recorded. Good clinical documentation should additionally include the product or formulation, dose, route, site, expiration date when captured locally, and the source and certainty of reconstructed vaccine history.
Refusal and deferral also require careful documentation. A useful note identifies the vaccine discussed, why it was recommended, the patient’s specific concern, counseling provided, information offered, whether the patient declined or deferred, and when the discussion will be revisited. Pejorative terminology should be avoided. “Declined after counseling because of concern about a prior adverse reaction” is more clinically useful than “noncompliant.”
Table 3. Core Documentation Elements
| Element | Why it matters | Practical note |
| Vaccine name, product, manufacturer, and lot | Traceability and adverse-event review | Include the formulation when clinically relevant |
| Date, dose, route, and site | Dose validity and safety review | Helps identify invalid, duplicate, or administration-error doses |
| VIS edition date and date provided | Federal documentation requirement for covered vaccines | Record when the VIS is provided electronically or on paper |
| Administrator and facility | Legal record and continuity | Include the name, title, and required address information |
| Prior record source | Catch-up reliability | Identify the registry, pharmacy, outside record, serology, or patient report |
| Refusal or deferral | Continuity and risk communication | Document the concern, counseling, decision, and revisit plan |
Safety, Contraindications, and Product-Specific Nuance
Contraindications and precautions must be assessed vaccine by vaccine. A severe allergic reaction after a prior dose or to a vaccine component is a contraindication to many vaccines, but the reaction history and implicated component should be characterized carefully. Moderate or severe acute illness is generally a precaution rather than a permanent contraindication. Pregnancy, severe immunocompromise, age, and specific prior adverse events may alter vaccine selection or timing.
Live Vaccines and Immunosuppression
Live attenuated vaccines require particular care. MMR and varicella vaccines are generally contraindicated during pregnancy and in persons with severe immunocompromise. Selected immunocompromised patients may remain eligible for specific live vaccines depending on the underlying condition, immune parameters, HIV status, medication intensity, timing relative to chemotherapy or transplantation, and specialist guidance.
Clinicians prescribing biologic therapy, high-dose systemic corticosteroids, chemotherapy, transplant immunosuppression, JAK inhibitors, or other immune-modifying therapies should review vaccine status and administer indicated vaccines before immunosuppression when clinically feasible. The timing required before therapy varies by vaccine and treatment. Urgent immunosuppressive treatment should not automatically be delayed solely to complete vaccination without coordinated assessment of disease urgency, infection risk, expected vaccine response, and future vaccine eligibility.
Pneumococcal Vaccination
Current CDC recommendations generally call for pneumococcal conjugate vaccination in adults aged 50 years or older who have not received a recommended conjugate vaccine or whose history is unknown. Options include PCV15, PCV20, or PCV21. When PCV15 is selected, PPSV23 is generally needed later, with the interval modified in selected high-risk patients. A subsequent PPSV23 dose is not recommended after PCV20 or PCV21. Patients with prior PCV13, PPSV23, or mixed product histories require the current decision pathway rather than a simplified age-only rule.
Adult RSV Vaccination
CDC currently recommends a single RSV vaccine dose for all adults aged 75 years or older and for adults aged 50 through 74 years who are at increased risk of severe RSV illness. Recognized risk factors include qualifying chronic cardiovascular or respiratory disease, end-stage renal disease or dialysis, selected forms of complicated diabetes, immunocompromise, frailty, and residence in a nursing home or other long-term care setting. Healthy adults aged 50 through 74 years are not recommended RSV vaccination solely on the basis of age.
RSV vaccination is not currently an annual vaccination. Adults who have already received an RSV vaccine should not receive another dose at this time unless future recommendations change. FDA licensure and CDC recommendations are related but not identical; an FDA-approved age indication does not independently establish a population-level CDC recommendation.
FDA requires Guillain-Barre syndrome warnings in the prescribing information for Abrysvo and Arexvy. A postmarketing observational study suggested an increased risk during the 42 days after vaccination. FDA concluded that the overall evidence suggests an increased risk but is insufficient to establish a causal relationship. FDA also determined that the benefits of vaccination continue to outweigh the risks in approved populations. Clinicians should neither ignore this safety signal nor describe the association as proven causation.
Maternal and Infant RSV Prevention
Abrysvo is the only RSV vaccine used for maternal vaccination. CDC guidance identifies administration at 32 weeks 0 days through 36 weeks 6 days of gestation during the recommended seasonal window, generally September through January in most of the continental United States.
The 2026 ACOG maternal schedule recommends maternal Abrysvo during the first eligible pregnancy and states that repeat maternal RSV vaccination is not indicated in a subsequent pregnancy; the infant should instead receive a long-acting RSV monoclonal antibody when eligible. Because maternal guidance has changed and may differ among organizations, clinicians should verify current ACOG, CDC, product-labeling, and local recommendations before administration.
In most circumstances, an infant is protected through either maternal RSV vaccination or infant immunization with a long-acting RSV monoclonal antibody, not both. Nirsevimab and clesrovimab are monoclonal antibodies rather than vaccines. Infant antibody is recommended when the mother was not vaccinated during pregnancy, maternal vaccination status is unknown, or the infant was born within 14 days of maternal vaccination. Additional exceptions may apply in selected high-risk circumstances.
COVID-19 Vaccination
The current 2025-2026 CDC guidance uses individual-based decision-making for people aged 6 months or older. The risk-benefit balance is most favorable in people at increased risk of severe COVID-19. Recommended products, dose numbers, and intervals vary by age, prior vaccination history, product, and immune status.
People who are moderately or severely immunocompromised follow a modified schedule. Clinicians should verify the current formulation, FDA approval or authorization, age indication, previous doses, and minimum and recommended intervals before administration. Current CDC COVID-19 guidance states that vaccination should not be delayed solely because a patient is receiving immunosuppressive therapy, although timing may be individualized to improve response when clinically feasible.
Meningococcal Products
MenABCWY products are an option when both MenACWY and MenB vaccination are indicated at the same visit. They should not be treated as a universal replacement for either component. MenB brand and series requirements remain product-specific, and clinicians should verify whether subsequent doses must use the same brand or a compatible pentavalent product.
Table 4. Selected Safety and Product-Specific Issues
| Issue | Key clinical point | Practical action |
| Severe allergic reaction | Contraindication for many vaccines when linked to a prior dose or component | Characterize the reaction and review ingredients |
| Moderate or severe acute illness | Usually a precaution, not a permanent contraindication | Defer when clinically appropriate and establish a rescheduling plan |
| Live vaccines | Often contraindicated during pregnancy or severe immunocompromise | Review before immunosuppression and apply vaccine-specific guidance |
| Pneumococcal vaccines | Product history determines whether another conjugate vaccine or PPSV23 is needed | Use the current CDC decision pathway |
| Adult RSV vaccines | Recommendation depends on age, risk, prior vaccination, and current safety information | Confirm eligibility and discuss the GBS signal proportionately |
| Maternal RSV vaccination | Abrysvo is the maternal product; gestational and seasonal timing are specific | Verify current ACOG, CDC, and labeling guidance |
| Infant RSV antibodies | Nirsevimab and clesrovimab provide passive protection and are not vaccines | Determine eligibility from maternal vaccination history, birth timing, age, and risk |
| COVID-19 vaccines | Product and schedule vary by age, immune status, and prior vaccination | Verify the current formulation and schedule before administration |
| MenABCWY vaccines | Appropriate when MenACWY and MenB are both indicated | Follow product-specific series and interchangeability rules |
The Subspecialist’s Role
Subspecialists do not need to become vaccine-program directors, but they should recognize when their disease area or prescribed therapy alters infection risk, vaccine response, or future vaccine eligibility.
Cardiologists should review influenza, COVID-19, pneumococcal, and RSV vaccination in patients with heart failure, ischemic heart disease, advanced age, frailty, or recurrent hospitalization. Pulmonologists should integrate respiratory vaccination into the care of patients with COPD, asthma, bronchiectasis, interstitial lung disease, pulmonary hypertension, and chronic respiratory failure.
Nephrologists should prioritize hepatitis B, pneumococcal, influenza, COVID-19, and transplant-related vaccine planning in patients with advanced chronic kidney disease or receiving dialysis. Rheumatologists and gastroenterologists should review vaccination status and administer indicated vaccines, when feasible, before biologic therapy, small-molecule immunosuppression, or prolonged high-dose corticosteroid exposure. Oncologists and transplant clinicians should coordinate vaccine timing around chemotherapy, cellular therapy, transplantation, and immune reconstitution.
A practical rule is to conduct immunization review before treatment becomes urgent whenever the condition or planned therapy increases infection severity, reduces expected vaccine response, or limits future use of live vaccines.
Vaccine Hesitancy: A Clinician-Facing Playbook
Vaccine hesitancy is not a single belief. It may reflect safety concerns, mistrust, prior adverse experiences, fear of immune activation, pregnancy concerns, fertility concerns, neurologic concerns, schedule fatigue, political identity, misinformation, or confusion created by changing recommendations. Clinicians should not assume that all hesitation is irrational, fixed, or responsive to the same communication strategy.
A clear clinician recommendation remains important. Observational studies in pediatric encounters have found that presumptive, confident openings are associated with greater vaccine acceptance than open-ended participatory openings in some settings. These studies demonstrate an association and do not establish that one communication style will be effective for every patient.
More recent intervention evidence is mixed. A 2025 cluster randomized trial of a tiered presumptive and motivational-interviewing strategy did not demonstrate a significant overall improvement in childhood vaccine uptake across all participating sites, although effects varied by location. A 2026 cluster randomized trial in Veterans Health Administration facilities found that motivational-interviewing-informed education for clinicians and staff did not significantly increase COVID-19 or influenza vaccine uptake. A 2025 systematic review similarly concluded that evidence comparing motivational and educational interventions was heterogeneous and generally of limited certainty.
The appropriate interpretation is not that communication does not matter. Rather, a clear recommendation should be combined with listening, patient-specific risk discussion, accurate characterization of uncertainty, and follow-up.
A practical opening is specific: “You are due for pneumococcal vaccination. Based on your age and COPD, I recommend giving it at this visit.” If the patient hesitates, the next step is not a generic lecture. The clinician should identify which concern matters most and address that concern directly.
Patients worried about neurologic adverse events require a different discussion from those worried about pregnancy, fertility, autoimmune disease, myocarditis, multiple vaccines at one visit, or changing recommendations. Good counseling distinguishes:
- A safety signal from established causality
- Absolute risk from relative risk
- Prevention of infection from prevention of severe disease
- Expected population benefit from an individualized recommendation
- Patient preference from a medical contraindication
Table 5. Vaccine-Confidence Playbook
| Patient concern | Better response | Avoid |
| “I do not know who to trust.” | Acknowledge conflicting messages and identify the schedule, evidence, or source being used | “Just trust the science.” |
| “That is too many vaccines at once.” | Explain coadministration evidence and offer clinically appropriate prioritization when needed | Dismissing the concern or promising that adverse effects cannot occur |
| “I heard it causes neurologic problems.” | Separate the safety signal, observed association, absolute risk, and causality assessment | Describing an association as proven causation or denying that a signal exists |
| “I never get sick.” | Discuss severe-disease risk, comorbidities, exposure, and consequences | Promising complete prevention of infection |
| “I want to wait.” | Clarify what information or event would change the decision and establish a revisit date | Leaving the decision indefinitely open-ended |
| Prior adverse event | Characterize the reaction and determine whether it represents a contraindication, precaution, or unrelated event | Treating every post-vaccination symptom as a contraindication |
Shared Clinical Decision-Making Without Abdication
Shared clinical decision-making does not mean withholding a recommendation. It is most useful when the expected benefit and risk vary by age, comorbidity, exposure, immune status, pregnancy, prior vaccination, and patient values.
For RSV, CDC recommends vaccination rather than optional age-only discussion for unvaccinated adults aged 50 through 74 years who meet increased-risk criteria and for all adults aged 75 years or older. A healthy adult aged 50 through 74 years does not qualify solely on the basis of age.
An adult considering HPV vaccination after age 26 requires discussion of prior and potential future exposure, the likelihood of benefit, and the fact that vaccination prevents new infection rather than treating established HPV disease. For hepatitis B, routine vaccination is recommended for adults aged 19 through 59 years. Adults aged 60 years or older should be vaccinated when risk factors are present and may receive vaccination when seeking protection. When screening is indicated, a hepatitis B triple panel can be obtained, but testing should not become an unnecessary barrier to vaccination.
The clinician should document shared decision-making as a process. The note should identify the recommendation category, patient-specific risk, material uncertainty, patient concern, decision, and follow-up plan.
Implementation: Build a Vaccine-Reliable Clinic
Reliable vaccination workflows are system-based. They do not depend on one clinician remembering every vaccine during a short visit.
A practical system includes regular vaccine reconciliation, EHR prompts linked to age and diagnosis, immunosuppression alerts, pregnancy-specific prompts, registry queries, standing orders where legally and institutionally permitted, previsit planning for multidose series, and pharmacist- or nurse-led follow-up. Discharge workflows should include vaccine reconciliation for patients hospitalized with cardiopulmonary disease, advanced kidney disease, diabetes complications, immunosuppression, splenectomy, transplant evaluation, or anticipated long-term care placement.
Clinics should explicitly define which schedule sources govern local practice. The policy should identify the schedule version and publication date, the clinical owner responsible for updates, the process for reconciling CDC and specialty-society recommendations, and the role of FDA labeling, payer policy, state requirements, and institutional review.
When guidance differs, the discrepancy should not be hidden. The record should identify which recommendation was applied and why it was considered appropriate for the patient and practice setting.
Limitations
This article is not a substitute for the current CDC schedule, AAP schedule, ACOG maternal immunization guidance, FDA labeling, state requirements, or local institutional policy. Vaccine recommendations may change during the year, and products may be added, discontinued, reformulated, restricted, or supplied unevenly.
Evidence on vaccine communication remains heterogeneous. Clinician recommendation, motivational interviewing, targeted education, and structured communication may be useful, but no script reliably improves uptake in every population or health system. Intervention effects depend on the population, implementation fidelity, clinician training, access, follow-up, and structural barriers to vaccination.
Safety signals must also be interpreted carefully. A postmarketing signal may be clinically important even when causality has not been established. Conversely, uncertainty about causality should not be used to dismiss a patient’s concern. Clinicians should discuss risk proportionately, compare it with disease risk, and document individualized decision-making.
Vaccination and catch-up in 2026 are best approached as a clinical reliability process. Clinicians must know where to find the current schedule, how to validate prior doses, when not to restart a delayed series, how medical risk and immunosuppression alter recommendations, how to document legally and clinically meaningful information, and how to respond to hesitancy without becoming dismissive or passive.
The strongest vaccine conversation is clear, specific, evidence-informed, and revisitable. It provides a recommendation, explains the patient-specific rationale, acknowledges material uncertainty, and documents the decision. For primary care clinicians, subspecialists, pharmacists, and advanced practice clinicians, immunization review should be treated as part of disease management rather than as a separate preventive-care afterthought.
Clinical Update Disclaimer
Vaccine schedules, product indications, safety warnings, formulations, age cutoffs, dosing intervals, and recommendations for pregnancy or immunocompromised patients may change after publication. The U.S. schedule environment in 2026 includes differences among current CDC, AAP, and ACOG recommendations. Before making a patient-specific recommendation or administering a product, clinicians should review the current applicable immunization schedule, FDA-approved prescribing information or authorization, CDC clinical considerations, relevant specialty-society guidance, state requirements, and institutional policy. This article is intended for professional education and does not replace patient-specific clinical judgment.
References
American Academy of Family Physicians. (2026). Immunization and vaccine schedules and resources. Retrieved June 28, 2026, from https://www.aafp.org/clinical-insights/immunizations-and-vaccines/immunizations-schedules-resources
American Academy of Pediatrics. (2026). Immunization schedule. Retrieved June 28, 2026, from https://www.aap.org/en/patient-care/immunizations/immunization-schedule/
American College of Obstetricians and Gynecologists. (2026). 2026 maternal immunization schedule. Retrieved June 28, 2026, from https://www.acog.org/clinical-information/maternal-immunization-schedule
American College of Obstetricians and Gynecologists. (2026). Maternal immunization. Retrieved June 28, 2026, from https://www.acog.org/programs/immunization-for-women/maternal-immunization
Amin, A. B., Duffy, J., Mbaeyi, S. A., et al. (2026). Use of the GSK MenACWY-CRM/MenB-4C pentavalent meningococcal vaccine: Recommendations of the Advisory Committee on Immunization Practices – United States, 2026. MMWR Morbidity and Mortality Weekly Report, 75(1), 7-14. https://www.cdc.gov/mmwr/volumes/75/wr/mm7501a2.htm
Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J., & Kempe, A. (2017). Increasing vaccination: Putting psychological science into action. Psychological Science in the Public Interest, 18(3), 149-207. https://doi.org/10.1177/1529100618760521. PMID: 29611455
Britton, A., Roper, L. E., Kotton, C. N., et al. (2024). Use of respiratory syncytial virus vaccines in adults aged 60 years or older: Updated recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morbidity and Mortality Weekly Report, 73, 696-702. https://doi.org/10.15585/mmwr.mm7332e1. PMID: 39146277
Centers for Disease Control and Prevention. (2024). Contraindications and precautions. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
Centers for Disease Control and Prevention. (2024). Timing and spacing of immunobiologics. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
Centers for Disease Control and Prevention. (2025). 2025-2026 COVID-19 vaccination guidance. Retrieved June 28, 2026, from https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html
Centers for Disease Control and Prevention. (2025). COVID-19 vaccination guidance for people who are immunocompromised. Retrieved June 28, 2026, from https://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html
Centers for Disease Control and Prevention. (2025). Adult immunization schedule by age: Recommendations for ages 19 years or older, United States, 2025. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html
Centers for Disease Control and Prevention. (2025). Adult immunization schedule addendum. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-addendum.html
Centers for Disease Control and Prevention. (2025). Catch-up immunization schedule for children and adolescents. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-catch-up.html
Centers for Disease Control and Prevention. (2025). Child and adolescent immunization schedule by age: Recommendations for ages 18 years or younger, United States, 2025. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
Centers for Disease Control and Prevention. (2025). Vaccine administration: After giving vaccine. Retrieved June 28, 2026, from https://www.cdc.gov/vaccines/hcp/administration/after.html
Centers for Disease Control and Prevention. (2025). RSV vaccine guidance for pregnant women. Retrieved June 28, 2026, from https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/pregnant-people.html
Centers for Disease Control and Prevention. (2026). Pneumococcal vaccine recommendations. Retrieved June 28, 2026, from https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
Food and Drug Administration. (2025). FDA requires Guillain-Barre syndrome warning in the prescribing information for RSV vaccines Abrysvo and Arexvy. Retrieved June 28, 2026, from https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-guillain-barre-syndrome-gbs-warning-prescribing-information-rsv-vaccines-abrysvo-and
Food and Drug Administration. (2025). MNEXSPIKE. Retrieved June 28, 2026, from https://www.fda.gov/vaccines-blood-biologics/mnexspike
Food and Drug Administration. (2025). PENMENVY. Retrieved June 28, 2026, from https://www.fda.gov/vaccines-blood-biologics/penmenvy
Grohskopf, L. A., Blanton, L. H., Ferdinands, J. M., et al. (2025). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2025-26 influenza season. MMWR Morbidity and Mortality Weekly Report, 74(32), 500-507. https://doi.org/10.15585/mmwr.mm7432a2. PMID: 40879559
Issa, A. N., Wodi, A. P., Moser, C. A., & Cineas, S. (2025). Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger: United States, 2025. MMWR Morbidity and Mortality Weekly Report, 74, 26-29. https://doi.org/10.15585/mmwr.mm7402a2
Kampmann, B., Madhi, S. A., Munjal, I., et al. (2023). Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. The New England Journal of Medicine, 388(16), 1451-1464. https://doi.org/10.1056/NEJMoa2216480. PMID: 37018474
Kobayashi, M., Leidner, A. J., Gierke, R., et al. (2025). Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged 50 years or older: Recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morbidity and Mortality Weekly Report, 74, 1-8. https://doi.org/10.15585/mmwr.mm7401a1. PMID: 39773952
Labbe, S., Gosselin Boucher, V., Gagneur, A., et al. (2025). Addressing vaccine hesitancy: A systematic review comparing the efficacy of motivational versus educational interventions on vaccination uptake. Translational Behavioral Medicine, 15(1), ibae069. https://doi.org/10.1093/tbm/ibae069. PMID: 40167044
O’Leary, S. T., & Committee on Infectious Diseases. (2026). Recommended childhood and adolescent immunization schedule: United States, 2026: Policy statement. Pediatrics, 157(3), e2025075754. https://doi.org/10.1542/peds.2025-075754. PMID: 41582321
Opel, D. J., Heritage, J., Taylor, J. A., et al. (2013). The architecture of provider-parent vaccine discussions at health supervision visits. Pediatrics, 132(6), 1037-1046. https://doi.org/10.1542/peds.2013-2037. PMID: 24190677
Opel, D. J., Mangione-Smith, R., Robinson, J. D., et al. (2015). The influence of provider communication behaviors on parental vaccine acceptance and visit experience. American Journal of Public Health, 105(10), 1998-2004. https://doi.org/10.2105/AJPH.2014.302425. PMID: 25790386
Papi, A., Ison, M. G., Langley, J. M., et al. (2023). Respiratory syncytial virus prefusion F protein vaccine in older adults. The New England Journal of Medicine, 388(7), 595-608. https://doi.org/10.1056/NEJMoa2209604. PMID: 36791160
Sandul, A. L., Weng, M. K., Murthy, N., et al. (2024). Updated recommendation of the Advisory Committee on Immunization Practices for hepatitis B vaccination of adults. MMWR Morbidity and Mortality Weekly Report, 73(48), 1106-1108. https://www.cdc.gov/mmwr/volumes/73/wr/mm7348a3.htm. PMID: 39636783
Wilson, E., Goswami, J., Baqui, A. H., et al. (2023). Efficacy and safety of an mRNA-based RSV prefusion F vaccine in older adults. The New England Journal of Medicine, 389(24), 2233-2244. https://doi.org/10.1056/NEJMoa2307079. PMID: 38091530
Wodi, A. P., Issa, A. N., Moser, C. A., & Cineas, S. (2025). Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2025. MMWR Morbidity and Mortality Weekly Report, 74, 30-33. https://doi.org/10.15585/mmwr.mm7402a3. PMID: 39820474
Recent Articles
Integrative Perspectives on Cognition, Emotion, and Digital Behavior
Sleep-related:
Longevity/Nutrition & Diet:
Philosophical / Happiness / Social:
Other:
Modern Mind Unveiled
Developed under the direction of David McAuley, Pharm.D., this collection explores what it means to think, feel, and connect in the modern world. Drawing upon decades of clinical experience and digital innovation, Dr. McAuley and the GlobalRPh initiative translate complex scientific ideas into clear, usable insights for clinicians, educators, and students.
The series investigates essential themes–cognitive bias, emotional regulation, digital attention, and meaning-making—revealing how the modern mind adapts to information overload, uncertainty, and constant stimulation.
At its core, the project reflects GlobalRPh’s commitment to advancing evidence-based medical education and clinical decision support. Yet it also moves beyond pharmacotherapy, examining the psychological and behavioral dimensions that shape how healthcare professionals think, learn, and lead.
Through a synthesis of empirical research and philosophical reflection, Modern Mind Unveiled deepens our understanding of both the strengths and vulnerabilities of the human mind. It invites readers to see medicine not merely as a science of intervention, but as a discipline of perception, empathy, and awareness–an approach essential for thoughtful practice in the 21st century.
The Six Core Themes
I. Human Behavior and Cognitive Patterns
Examining the often-unconscious mechanisms that guide human choice-how we navigate uncertainty, balance logic with intuition, and adapt through seemingly irrational behavior.
II. Emotion, Relationships, and Social Dynamics
Investigating the structure of empathy, the psychology of belonging, and the influence of abundance and selectivity on modern social connection.
III. Technology, Media, and the Digital Mind
Analyzing how digital environments reshape cognition, attention, and identity- exploring ideas such as gamification, information overload, and cognitive “nutrition” in online spaces.
IV. Cognitive Bias, Memory, and Decision Architecture
Exploring how memory, prediction, and self-awareness interact in decision-making, and how external systems increasingly serve as extensions of thought.
V. Habits, Health, and Psychological Resilience
Understanding how habits sustain or erode well-being-considering anhedonia, creative rest, and the restoration of mental balance in demanding professional and personal contexts.
VI. Philosophy, Meaning, and the Self
Reflecting on continuity of identity, the pursuit of coherence, and the construction of meaning amid existential and informational noise.
Keywords
Cognitive Science • Behavioral Psychology • Digital Media • Emotional Regulation • Attention • Decision-Making • Empathy • Memory • Bias • Mental Health • Technology and Identity • Human Behavior • Meaning-Making • Social Connection • Modern Mind
Video Section
